1. Home
  2. RAIL vs SPRO Comparison

RAIL vs SPRO Comparison

Compare RAIL & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FreightCar America Inc.

RAIL

FreightCar America Inc.

HOLD

Current Price

$9.28

Market Cap

149.9M

Sector

Industrials

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.20

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAIL
SPRO
Founded
1901
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Railroads
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
149.9M
156.3M
IPO Year
2005
2017

Fundamental Metrics

Financial Performance
Metric
RAIL
SPRO
Price
$9.28
$2.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
170.6K
1.6M
Earning Date
05-04-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
134.94
111.81
EPS
1.15
N/A
Revenue
$500,991,000.00
$66,802,000.00
Revenue This Year
$6.54
N/A
Revenue Next Year
$30.90
$300.00
P/E Ratio
$8.10
N/A
Revenue Growth
N/A
39.24
52 Week Low
$7.27
$1.80
52 Week High
$14.90
$3.09

Technical Indicators

Market Signals
Indicator
RAIL
SPRO
Relative Strength Index (RSI) 67.91 38.98
Support Level $9.00 $2.19
Resistance Level $10.09 $2.47
Average True Range (ATR) 0.46 0.26
MACD 0.20 -0.06
Stochastic Oscillator 86.71 29.54

Price Performance

Historical Comparison
RAIL
SPRO

About RAIL FreightCar America Inc.

FreightCar America Inc is a diversified manufacturer and supplier of railcars and railcar components. It designs and manufactures a variety of railcar types for transportation of bulk commodities and containerized freight products in North America. The company also provides railcar rebody and repair services, railcar conversion services, and supplies railcar parts. The company has two segments: Manufacturing and Aftermarket. The majority of the company's revenue is derived from the Manufacturing segment, which includes new railcar manufacturing, used railcar sales, and various conversions and rebodies. Geographically, it generates the maximum revenue from the United States.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: